Desire, and What Changes

Sexual desire in midlife is treated in public conversation as either a punchline or a tragedy, and in clinical settings frequently not at all. What it actually is: a specific set of changes, some hormonal, some mechanical, some relational, and each of them addressable — but only if you can tell them apart.

The most common mistake

A large number of women arrive at the conclusion that desire has gone, when what has actually happened is that sex has started to hurt.

Pain is a highly effective suppressant of desire. If penetration is uncomfortable — because vaginal tissue has thinned, lubrication has reduced, elasticity has changed — the brain quite sensibly stops generating enthusiasm for it. That isn't a loss of desire. It's an appropriate response to anticipated discomfort.

The distinction is critical because the treatments are entirely different. Genitourinary syndrome of menopause is treatable with local vaginal estrogen, which is low-dose, well evidenced, and acts mostly where it's applied. Desire itself is a more complicated conversation.

So the first question is not "why don't I want it" but "does it hurt, or is it uncomfortable, or does it just feel like nothing." Different answers, different routes.

What changes in desire itself

Spontaneous desire declines; responsive desire often doesn't. Sexual desire has two broad modes. Spontaneous desire arrives unprompted. Responsive desire emerges in response to stimulation and context — it starts after things start.

Spontaneous desire tends to decline with age in both sexes. Responsive desire is more durable. Many women in midlife report they no longer want sex in advance but do enjoy it once underway — and then conclude something is broken, because the cultural script only recognises the spontaneous version.

Recalibrating expectation here resolves a meaningful proportion of the distress, without any treatment at all.

Arousal takes longer and needs more. Blood flow changes affect genital arousal, and the time and directness of stimulation required increases. This is normal and it is not a verdict on attraction.

Testosterone declines gradually. Women produce testosterone, and it contributes to desire. Unlike estrogen, it declines slowly with age rather than dropping at menopause — so it's less often the main explanation than assumed, though it can be relevant.

Everything else is loud. Exhaustion, low mood, resentment, body image, and the specific difficulty of moving from carer or manager into a sexual register within the same evening. None of this is hormonal and all of it counts.

Treatment: what exists

Local vaginal estrogen for pain, dryness and tissue change. Effective, low risk, and covered in more detail in the article on genitourinary syndrome. If sex hurts, start here.

Systemic hormone therapy may help desire indirectly by improving sleep, mood and general symptom load. It's not primarily a treatment for low desire.

Testosterone. This is where care is warranted. A global consensus position statement produced by multiple international societies concluded that the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder in postmenopausal women. NICE says testosterone supplementation can be considered for low sexual desire if HRT alone is not effective.

In practice this means: it can be appropriate, in a specific situation, usually after estrogen is already optimised. In the UK there's no licensed female testosterone product, so it's prescribed off-label using a fraction of a male dose, with blood monitoring. Testosterone marketed as a general energy or wellbeing treatment for women has no evidence behind it and the consensus statement is explicit about that.

Psychosexual therapy. Genuinely useful and under-referred, particularly where a pattern of avoidance has become established, or where the couple's dynamic has reorganised around a problem neither has discussed directly.

The relationship question

If sex has stopped, the reason is often not desire and not tissue. It's that a period of pain or exhaustion produced avoidance, avoidance produced awkwardness, and now nobody initiates because a refusal has become too loaded.

This unwinds more easily when it's named early. It gets much harder after two years of silence.

Worth saying too: there is no obligation to want sex. Some women in this stage conclude they'd rather not, and that is a legitimate outcome rather than a problem to be solved. The distinction that matters is whether it's a preference or a loss — whether it feels like a decision or like something taken from you. The second one is worth treating. The first isn't a condition.

What to bring to an appointment

Whether it hurts. Whether desire is absent or just no longer spontaneous. Whether anything else changed at the same time — sleep, mood, medication. Whether you're distressed by it, which is genuinely the criterion that determines whether it needs treating.

And if you get brushed off, ask for referral to someone with menopause or psychosexual expertise. This is an area where clinician confidence varies widely, and where a different appointment often produces a completely different conversation.

Sources

- Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. Climacteric. 2019;22(5):429–434. - National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated 2024. - Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy. Menopause. 2014;21(10):1063–1068. - The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. - Basson R. The female sexual response: a different model. Journal of Sex and Marital Therapy. 2000;26(1):51–65.